Expansion of Pharmaceutical Production, Valued at R$ 500 Million, Consolidates Minas Gerais as a Global Reference in the Health Sector
The Danish pharmaceutical company Novo Nordisk announced a new investment of R$ 500 million in Montes Claros, Minas Gerais. The amount will be allocated to the installation of a production line aimed at enzymes essential for drug manufacturing. This expansion is strategic to meet the growing global demand for treatments of chronic diseases such as diabetes and obesity, according to the EM website.
Among the highlights are the enzymes enteropeptidase and ALP, crucial in the production of insulin and GLP-1 analogs, such as Ozempic and Wegovy. Montes Claros is the sole supplier of these components for Novo Nordisk’s matrix in Denmark, consolidating its position as a global hub in the sector.
Investment Details
The project, with construction starting in January 2025, will create 400 indirect jobs during construction and 40 direct jobs in operation. Production is expected to begin in 2027, tripling current capacity.
-
While the Brazilian government is still discussing whether or not to create a state-owned company for rare earths, a Canadian company has already signed agreements to acquire two giant projects in the Northeast with potential for deposits that China dominates and the whole world disputes.
-
Who is the richest athlete in Brazil, who has a net worth of R$ 6.5 billion, a R$ 70 million mansion, a luxury apartment, and millionaire contracts?
-
Brazil becomes a target for mining investors, but only 27% of its territory is precisely mapped, while 10 times more Brazilian mining companies seek capital on the Toronto Stock Exchange; a study points out obstacles and projects up to US$ 77 billion in investments between 2026 and 2030.
-
The Chamber approved new rules for the naturalization of foreigners in Brazil that require at least four years of uninterrupted residence, proof of lawful income and a clean record, and even those who meet all these requirements will not have an automatic right to Brazilian citizenship.
Global Relevance
- The Montes Claros unit is responsible for 25% of Novo Nordisk’s global insulin production.
- It represents 12% of global consumption and 25% of Brazilian pharmaceutical exports.
- More than 70% of the insulin supplied to SUS is produced by the company, serving 4.3 million Brazilians per year.

Sustainability and Innovation
In addition to the new investment, the company had already announced in 2023 a contribution of R$ 864 million for the modernization of its facilities. At the same time, in partnership with Elétron Energy, Novo Nordisk is investing R$ 245 million in the construction of a solar park, with a capacity to generate 90 MWh. The project will become operational in 2025, ensuring that all the energy used by the unit comes from renewable sources.
Regional Impacts and Government Support
The governor of Minas Gerais, Romeu Zema, highlighted the role of the investment in transforming Montes Claros into one of the main pharmaceutical hubs in the country. According to him, the state is on track to reach half a trillion in private investments and create one million jobs by 2025.
Leadership Statements:
- Reinaldo Costa, Vice President of Novo Nordisk: “This investment reaffirms our commitment to Brazil and Minas Gerais.”
- Fernando Passalio, Secretary of Economic Development: “Montes Claros becomes a reference in innovation and sustainability, reinforcing the role of Minas Gerais in the energy transition.”
Minas Gerais also seeks to diversify its economy, reducing dependence on the mineral sector. In addition to the pharmaceutical industry, the state stands out in solar energy generation, representing 20% of national capacity, and attracts investments in sectors such as appliances and automotive.

o que nova nordisk está fazendo e um verdadeiro absurdo , no Brasil nunca faltou insulina nph e regular de 10 ml , há mais ou menos essa grande indústria simplesmente não está fabricando essas insulina que são super necessária para sobrevivência do diabeticos , tornado a vida do diabético um verdadeiro drama na sua saúde , agradecemos desde já que a nova nodisk resolva a falta de insulina nph e regular , desde já agradeço em nome do povo diabético do Brasil ,principalmente os menos favorecido!!!